Having trouble accessing articles? Reset your cache.

With Avastin on board, Tecentriq improves overall survival in HCC

Roche’s Tecentriq is the first checkpoint inhibitor to show a statistically significant survival benefit in the hard-to-treat indication of hepatocellular carcinoma. Unlike the other compounds, the anti-PD-L1 mAb was combined with a VEGF inhibitor to gain a survival advantage over standard-of-care Nexavar sorafenib.

Roche (SIX:ROG; OTCQB:RHHBY)

Read the full 469 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE